Skip to main content

Advertisement

SpringerLink
Log in

Malignancy and rheumatoid arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The occurrence of cancer is not an infrequent event in patients with rheumatoid arthritis (RA). Indeed, following diagnosis of RA at a typical age (55 years), one in five patients will be diagnosed with cancer. In the vast majority of such cases, the cancer has nothing to do with RA or its treatment; rather, it represents the “background” risk applicable to all humans. In some cases, the cancer occurs as a result of factors also associated with the risk of developing RA (eg, smoking), even though no direct link exists between the cancer and the RA. In a fraction of cases, however, the cancer is causally associated with the RA disease or its treatments. This review summarizes our current understanding of the occurrence of cancer in RA, possible links to RA disease and to traditional and newer RA treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cancer Incidence in Sweden 2005. Stockholm: National Board of Health and Welfare; 2007.

  2. Ekstrom K, Hjalgrim H, Brandt L, et al.: Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003, 48:963–970.

    Article  PubMed  Google Scholar 

  3. Askling J, Fored CM, Brandt L, et al.: Risks of solid cancers in patients with rheumatoid arthritis and following treatment with tumor necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421–1426.

    Article  PubMed  CAS  Google Scholar 

  4. Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007, 56:1433–1439.

    Article  PubMed  CAS  Google Scholar 

  5. Franklin J, Lunt M, Bunn D, et al.: Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 2007, 56:790–798.

    Article  PubMed  Google Scholar 

  6. Mellemkjaer L, Alexander F, Olsen JH: Cancer among children of parents with autoimmune diseases. Br J Cancer 2000, 82:1353–1357.

    Article  PubMed  CAS  Google Scholar 

  7. Thomas E, Brewster DH, Black RJ, Macfarlane GJ: Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000, 88:497–502.

    Article  PubMed  CAS  Google Scholar 

  8. Tennis P, Andrews E, Bombardier C, et al.: Record linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the Province of Saskatchewan, Canada. J Clin Epidemiol 1993, 46:685–695.

    Article  PubMed  CAS  Google Scholar 

  9. Franklin J, Lunt M, Bunn D, et al.: Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006, 65:617–622.

    Article  PubMed  CAS  Google Scholar 

  10. Smedby KE, Hjalgrim H, Askling J, et al.: Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006, 98:51–60.

    Article  PubMed  Google Scholar 

  11. Mellemkjaer L, Linet MS, Gridley G, et al.: Rheumatoid arthritis and cancer risk. Eur J Cancer 1996, 32A:1753–1757.

    Article  PubMed  CAS  Google Scholar 

  12. Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740–1751.

    Article  PubMed  CAS  Google Scholar 

  13. Wolfe F, Michaud K: Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 2007, in press.

  14. Klareskog L, Padyukov L, Alfredsson L: Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007, 1:49–54.

    Article  CAS  Google Scholar 

  15. Caillard S, Dharnidharka V, Agodoa L, et al.: Post-transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2050, 80:1233–1243.

    Article  Google Scholar 

  16. Fortin AB, Piaserico S, Caforio AL, et al.: Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients. Arch Dermatol 2004, 140:1079–1085.

    Article  Google Scholar 

  17. Jacobs EJ, Thun MJ, Bain EB, et al.: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007, 99:608–615.

    Article  PubMed  CAS  Google Scholar 

  18. Initial scientific discussion for the approval of Arava. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Arava/169499en6.pdf. Accessed July 12, 2007.

  19. Ognenovski VM, Marder W, Somers EC, et al.: Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004, 31:1763–1767.

    PubMed  CAS  Google Scholar 

  20. Asten P, Barrett J, Symmons D: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999, 26:1705–1714.

    PubMed  CAS  Google Scholar 

  21. Chakravarty EF, Michaud K, Wolfe F: Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005, 32:2130–2135.

    PubMed  CAS  Google Scholar 

  22. Askling J, Fored CM, Baecklund E, et al.: Hematopoietic malignancies in rheumatoid arthritis. Lymphoma risk and characteristics following TNF-antagonists. Ann Rheum Dis 2005, 64:1414–1420.

    Article  PubMed  CAS  Google Scholar 

  23. Hakulinen T, Isomaki H, Knekt P: Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985, 78:29–32.

    Article  PubMed  CAS  Google Scholar 

  24. Baecklund E, Iliadou A, Askling J, et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54:692–701.

    Article  PubMed  Google Scholar 

  25. Bernatsky S, Lee JL, Rahme E: Non-Hodgkin’s lymphoma—meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford) 2007, 46:690–694.

    Article  CAS  Google Scholar 

  26. Baecklund E, Backlin C, Iliadou A, et al.: Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 2006, 54:3774–3781.

    Article  PubMed  CAS  Google Scholar 

  27. Fryzek JP, Ye W, Signorello LB, et al.: Incidence of cancer among patients with knee implants in Sweden, 1980–1994. Cancer 2002, 94:3057–3062.

    Article  PubMed  Google Scholar 

  28. Balkwill F: TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006, 25:409–416.

    Article  PubMed  CAS  Google Scholar 

  29. Madhusudan S, Foster M, Muthuramalingam SR, et al.: A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:6528–6534.

    Article  PubMed  CAS  Google Scholar 

  30. Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al.: Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005, 23:5950–5959.

    Article  PubMed  CAS  Google Scholar 

  31. Perkins ND: NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 2004, 14:64–69.

    Article  PubMed  CAS  Google Scholar 

  32. Hyrich KL, Silman AJ: Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety. J Rheumatol 2006, 33:831–833.

    PubMed  Google Scholar 

  33. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275–2285.

    Article  PubMed  CAS  Google Scholar 

  34. Okada SK, Siegel JN: Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006, 296:2201–2202; author reply 2203–2204.

    Article  PubMed  CAS  Google Scholar 

  35. Remicade [prescribing information]. Available at http://www.remicade.com/pdf/HCP_PPI.pdf. Accessed July 12, 2007.

  36. Humira [prescribing information]. Available at http://www.rxabbott.com/pdf/humira.pdf. Accessed July 12, 2007.

  37. Enbrel [prescribing information]. Available at http://www.enbrel.com/pdf/enbrel_pi.pdf. Accessed July 12, 2007.

  38. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005, 352:351–361.

    Article  Google Scholar 

  39. Setoguchi S, Solomon DH, Weinblatt ME, et al.: Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2757–2764.

    Article  PubMed  CAS  Google Scholar 

  40. Watson KD: Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with RA. Ann Rheum Dis 2006, 45(Suppl 1):I10.

    Google Scholar 

  41. Carmona L: Overall cancer incidence is not increased in rheumatoid arthritis, although incidence by specific malignancies might be. Arthritis Rheum 2006, 54(Suppl 5):S360.

    Google Scholar 

  42. Askling J: No overall increase in cancer risk in RA patients treated with TNF-antagonists. Ann Rheum Dis 2007, 66(Suppl 11):54.

    Google Scholar 

  43. Brown SL, Greene MH, Gershon SK, et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151–3158.

    Article  PubMed  CAS  Google Scholar 

  44. Geborek P, Bladström A, Turesson C, et al.: TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005, 64:699–703.

    Article  PubMed  CAS  Google Scholar 

  45. Cohen SB, Emery P, Greenwald MW, et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793–2806.

    Article  PubMed  CAS  Google Scholar 

  46. Kineret [prescribing information]. Available at http://www.fda.gov/cder/foi/label/2003/anakamg062703LB.pdf. Accessed July 12, 2007.

  47. Annex I: Summary of Product Characteristics. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/orencia/H-701-PI-en.pdf. Accessed July 12, 2007.

  48. Weinblatt M, Combe B, Covucci A, et al.: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006, 54:2807–2816.

    Article  PubMed  CAS  Google Scholar 

  49. Morel J, Deschamps V, Toussirot E, et al.: Characteristics and survival of 26 patients with paraneoplastic arthritis. Ann Rheum Dis 2007, Epub ahead of print.

  50. Mikuls TR, Endo JO, Puumala SE, et al.: Prospective study of survival outcomes in Non-Hodgkin’s lymphoma patients with rheumatoid arthritis. J Clin Oncol 2006, 24:1597–1602.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Epidemiology Unit M9:01, Department of Medicine Solna, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden

    Johan Askling

Authors
  1. Johan Askling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johan Askling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Askling, J. Malignancy and rheumatoid arthritis. Curr Rheumatol Rep 9, 421–426 (2007). https://doi.org/10.1007/s11926-007-0067-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0067-1

Keywords

Search

Navigation